Wnt-β-Catenin
Wnt proteins form a family of highly conserved secreted signaling molecules that regulate cell-to-cell interactions during embryogenesis (embryonic induction, generation of cell polarity, and the specification of cell fate). Mutations in Wnt genes or Wnt pathway components lead to specific developmental defects, while various human diseases, including cancer, are caused by abnormal Wnt signaling. As currently understood, Wnt proteins bind to receptors of the Frizzled and LRP (low density Lipoprotein Receptor-related Protein) families on the cell surface. The result is alleviation of pathway inhibition caused by GSK-3β, APC, and Axin proteins. This stabilizes β-Catenin and promotes its nuclear translocation where it regulates target gene transcription together with Tcf/Lef proteins. During development, the Wnt/β-catenin pathway integrates signals from many other pathways including Retinoic acid, FGF, TGF-β, and BMP in many different cell-types and tissues. In addition, GSK-3β is also involved in glycogen metabolism and other key pathways, which has made its inhibition relevant to diabetes and neurodegenerative disorders[1],[2].
[1] Wnt signaling and stem cell control. Nusse, R. Cell Research 2008,18, 523-527.
[2] Wnt Signaling: Multiple Pathways, Multiple Receptors, and Multiple Transcription Factors. M. D. Gordon, R. Nusse. J Biol Chem. 2006, 281, 22429-22433.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
1909 | A 1070722 | Selective inhibitor of GSK-3 | €95.00 | |
2167 | AR-A 014418 | ATP-competitive GSK-3 inhibitor | €85.00 | |
5051 | Axon Ligands™ Cell signaling and Oncology compound library | Axon Ligands™ Cell signaling and Oncology compound library | Inquire | |
5053 | Axon Ligands™ Stem cell compound library | Axon Ligands™ Stem cell compound library | Inquire | |
2171 | AZD1080 | Selective inhibitor of GSK-3α and GSK-3β | €90.00 | |
3771 | AZD2858 | Potent and highly selective Glycogen Synthase Kinase-3β inhibitor | €95.00 | |
2194 | AZD2858 hydrochloride | Potent and highly selective Glycogen Synthase Kinase-3β inhibitor | €95.00 | |
1693 | BIO | GSK-3 inhibitor | €95.00 | |
2931 | BRD0705 | First-in-class, paralog selective GSK3α inhibitor | €210.00 | |
3153 | BRD5648 | Negative control compound of BRD0705 as a GSK3α inhibitor | €210.00 | |
3748 | C-82 | Specific inhibitor of Wnt/β-catenin signaling pathway | €110.00 | |
2161 | CCT 031374 hydrobromide | Inhibitor of TCF-dependent transcription of genes of Wnt signaling pathway | €60.00 | |
1126 | CHIR98014 | GSK-3 inhibitor | €99.00 | |
1386 | CHIR99021 | GSK-3 inhibitor | €60.00 | |
2435 | CHIR99021 dihydrochloride | GSK-3 inhibitor | €60.00 | |
2202 | CK2 inhibitor 10 | Potent and ATP-competitive inhibitor of CK2 | €105.00 | |
3279 | CKI-7 dihydrochloride | Selective inhibitor of Casein kinase 1 | €120.00 | |
3509 | Cromolyn disodium | GSK-3β inhibitor | €50.00 | |
1965 | CX 4945 hydrochloride | Inhibitor of Casein kinase 2 (CK2) | €90.00 | |
2574 | Defactinib | Orally available second generation inhibitor of FAK and PYK2 | €80.00 | |
3715 | E-7386 | CBP/beta-catenin modulator | Inquire | |
2568 | EML 425 | Potent reversible dual inhibitor of CBP and p300 (HAT/KAT3) | €95.00 | |
2686 | FH535 | Dual inhibitor of PPAR and Wnt/β-catenin signaling | €75.00 | |
2706 | FH535 sodium salt | Dual inhibitor of PPAR and Wnt/β-catenin signaling | €80.00 | |
1766 | ICG 001 | Specific inhibitor of Wnt/β-catenin signaling pathway | €115.00 | |
2135 | iCRT14 | Small-molecule inhibitor of the Wnt/wingless signaling pathway; CRT inhibitor | €135.00 | |
2133 | iCRT5 | β-Catenin-responsive transcription (CRT) inhibitor | €80.00 | |
2511 | IM 12 | GSK-3β inhibitor attenuating neuronal differentiation of human NPCs | €95.00 | |
3948 | ISX9 | Wnt/β-catenin signaling pathway agonist | Recently added | €110.00 |
2212 | IWP L6 | Highly potent porcupine (Porcn) inhibitor | €130.00 |